GlassScriptPhysician profile
John Andrew Puleo
NPI 1649262882
$4,485.50
in general payments reported to CMS, 2019-2025
26 companies · $989 in 2025
The $989 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $382 · 2021: $774 · 2022: $1,098 · 2023: $584 · 2024: $439 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $487.10 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $436.31 | 2019-2023 | |
| Pfizer INC. | $412.77 | 2019-2025 | |
| Philips North America LLC | $389.52 | 2022-2025 | (Ck7) Extended Holter, Extended Holter |
| Boston Scientific Corporation | $356.34 | 2019-2025 | Watchman Flx, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $348.70 | 2020-2024 | |
| Biotronik INC. | $305.39 | 2025 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Astrazeneca Pharmaceuticals LP | $283.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.34 | 2019-2025 | Jardiance |
| Abbott Laboratories | $179.93 | 2021-2025 | Aveir |
| Cvrx, INC. | $155.15 | 2022-2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $148.87 | 2020-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.43 | 2019-2025 | Lifevest |
| Medtronic, INC. | $142.22 | 2025 | Affera Mapping System |
| Esperion Therapeutics, INC. | $127.54 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $81.61 | 2021-2022 | |
| Amgen INC. | $50.78 | 2023-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $31.65 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $29.47 | 2019-2021 | |
| Edwards Lifesciences Corporation | $26.13 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $25.94 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $20.84 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $20.04 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $18.19 | 2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $16.79 | 2025 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $16.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Puleo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.